European Pharmaceutical Review

MARCH 4, 2024

These biopharmaceuticals encompass a range of products including vaccines, recombinant therapeutic proteins, tissues, cells and gene therapies – all sourced from living organisms. Indeed, in 2022, biologics constituted 40 percent of all US Food and Drug Administration (FDA) approved drugs, projecting a compound annual growth rate (CAGR) of 9.5

FDA 86

FDA Vaccines Immunization Compounding 86

ISPE

MARCH 8, 2023

5 , 8 Compounding pharmacies were commonly mentioned as sources of microbial cross-contamination, especially in the US. 9 , 15 This has led to compounding pharmacies completing high-volume activities such as mass repackaging, thereby increasing the risk of cross-contamination. million vials, 26 had to be recalled and destroyed.

Compounding 52

Compounding Compounding Pharmacies Packaging FDA 52

Pharmaceutical Technology

APRIL 24, 2023

Demand for biologics, including vaccines, is at an all-time high, in the post-Covid era. There are fewer sites for cell and gene therapies and vaccines – 90 companies with 127 facilities, as per GlobalData figures. The approval of the mRNA Covid-19 vaccine, which is a biologic, has thrust the modality even further into the spotlight.

Vaccines 52

Vaccines Compounding Pharmaceutical Companies Pharmaceutical Companies 52